**Acknowledgement**

I would like to thank to Aram Ríos for his invaluable cooperation in graphic design of the book chapter.

## **Author details**

Mario Pérez-Sayáns1 \*, Carmen Vidal-Real1 , José M. Suárez-Peñaranda2 and Abel García-García1

\*Address all correspondence to: perezsayans@gmail.com

1 Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain

2 Servicio de Anatomía Patológica, Hospital Clínica Universitario de Santiago, Spain

### **References**


**Acknowledgement**

book chapter.

76 Osteonecrosis

**Author details**

Mario Pérez-Sayáns1

**References**

I would like to thank to Aram Ríos for his invaluable cooperation in graphic design of the

1 Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry,

[1] Lapidus FI. Cancer and osteonecrosis of the lower jaw following irradiation.

[2] Gowgiel JM. Experimental radio-osteonecrosis of the jaws. Journal of Dental Research.

[3] Lawrence EA. Osteoradionecrosis of the mandible. The American Journal of Roentgenology

[4] Gallagher RE. Arsenic—new life for an old potion. New England Journal of Medicine.

[5] Cruse WP, Bellizzi R. A historic review of endodontics, 1689-1963, part 1. Journal of

[6] Dumlu A, Yalcinkaya S, Olgac V, Güvercin M. Osteomyelitis due to arsenic trioxide use

[7] Tal M, Kaufman A, Buchner A. Bone necrosis and dentine resorption caused by Toxavit:

[8] Bataineh A, Al-Omari M, Owais A. Arsenical necrosis of the jaws. International Endodontic

[9] Sanders B, McKelvy B, Adams D. Aseptic osteomyelitis and necrosis of the mandibular condylar head after intracapsular fracture. Oral Surgery, Oral Medicine, and Oral

for tooth devitalization. International Endodontic Journal. 2007;**40**(4):317-322

A case report. International Endodontic Journal. 1978;**11**(2):77-79

Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain 2 Servicio de Anatomía Patológica, Hospital Clínica Universitario de Santiago, Spain

, José M. Suárez-Peñaranda2

and Abel García-García1

\*, Carmen Vidal-Real1

\*Address all correspondence to: perezsayans@gmail.com

Stomatologiia (Mosk). 1950;**2**:34-36

and Radium Therapy. 1946 Jun;**55**:733-742

1960 Jan-Feb;**39**:176-197

1998;**339**(19):1389-1391

Endodontics. 1980;**6**(3):495-499

Journal. 1997;**30**(4):283-287

Pathology. 1977;**43**(5):665-670


[35] Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. The Journal of Clinical Endocrinology & Metabolism. 2007;**92**(3):1172-1175

[23] Ault A. Jaw necrosis affects 1 in 1,700 on oral bisphosphonates. Internal Medicine News.

[24] Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surgery, Oral

Medicine, Oral Pathology, Oral Radiology, and Endodontics. 2006;**102**(4):433-441

[25] Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. Journal of Oral and Maxillofacial

[26] Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treat-

[27] Hoff, AO, Toth, BB, Altundag, K, Guarneri, V, Adamus, A, Nooka, AK, Sayegh GG, Johnson MM, Gagel RF & Hortobagyi GN. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. Journal of Clinical Oncology. 2006;**24**(90180):8528-8528

[28] Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors.

[29] Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. Journal of Oral and Maxillofacial

[30] Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. British Journal of Haematology.

[31] Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in mul-

[32] Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: A possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron

[33] English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and Clinical

[34] Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide

tiple myeloma patients. Annals of Oncology. 2007 Dec;**18**(12):2015-2019

microscopy findings. Clinical Oral Investigations. 2010;**14**(3):271-284

polymorphism analysis. Blood. 2008 Oct 1;**112**(7):2709-2712.

Risk Management. 2010 Nov 19;**6**:579-583

ment. Journal of Oral and Maxillofacial Surgery. 2005 Nov;**63**(11):1567-1575

Journal of Clinical Oncology. 2006 Feb 20;**24**(6):945-952

2008;**41**(15):23-23

78 Osteonecrosis

Surgery. 2004 May;**62**(5):527-534

Surgery. 2008;**66**(4):625-631

2006;**134**(6):620-623


[61] Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. New England Journal of Medicine. 2010;**363**(25):2473-2474

[49] Bocci V. Ozone as Janus: This controversial gas can be either toxic or medically useful.

[50] Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results

[51] Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca J, et al. Surgical approach with Er: YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate

[52] Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw.

[53] Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery. 2012;**70**(7):1573-1583

[54] Atalay B, Yalcin S, Emes Y, Aktas I, Aybar B, Issever H, et al. Bisphosphonate-related osteonecrosis: Laser-assisted surgical treatment or conventional surgery?. Lasers in

[55] Rodriguez-Lozano, FJ, & Oñate-Sánchez, RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Medicina Oral, Patología

[56] Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related

[57] Schubert M, Klatte I, Linek W, Müller B, Döring K, Eckelt U, et al. The Saxon Bisphosphonate Register–Therapy and prevention of bisphosphonate-related osteone-

[58] Cella L, Oppici A, Arbasi M, Moretto M, Piepoli M, Vallisa D, et al. Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteo-

[59] Gonzalvez-Garcia M, Rodriguez-Lozano FJ, Villanueva V, Segarra-Fenoll D, Rodriguez-Gonzalez MA, Onate-Sanchez R, et al. Cell therapy in bisphosphonate-related osteone-

[60] Curi MM, Cossolin GSI, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonaterelated osteonecrosis of the jaws–an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. Journal of Oral and Maxillofacial

crosis of the jaw. The Journal of Craniofacial Surgery. 2013 May;**24**(3):e226–e228

Mediators of Inflammation. 2004 Feb;**13**(1):3-11

80 Osteonecrosis

of a phase I–II study. Oral Oncology. 2011;**47**(3):185-190

International Journal of Dentistry. 2014;**2014**:107690

Medical Science. 2011;**26**(6):815-823

Oral y Cirugía Bucal. 2016;**21**(5):e595

Surgery. 2011;**69**(9):2465-2472

osteonecrosis. Oral Oncology. 2011;**47**(5):420-424

crosis of the jaws. Oral Oncology. 2012;**48**(4):349-354

necrosis of the jaw. Head & Face Medicine. 2011;**7**(1):1

therapy (BPT). Lasers in Medical Science. 2010;**25**(1):101-113


[88] McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine. 2001;**344**(5):333-340

[74] Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. Journal of Pharmacology

[75] Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clinical

[76] Kapitola J, Zak J, Lacinova Z, Justova V. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiological Research.

[77] Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats.

[78] Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ven-

[79] Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in

[80] Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in mul-

[82] Hohnecker JA. Novartis 'Dear Doctor' Precautions Added to Label of Aredia and Zometa. Novartis Pharmaceuticals Corporation East Hanover USA. September 24, 2004.

[83] Almojaly, S. The Effect of the Bisphosphonate, Alendronate, on Primary Human Alveolar Bone Cells. State University of New York at Buffalo, ProQuest Dissertations Publishing;

[85] Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′ 446, a new, potent, heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research. 1994;**9**(5):

[86] Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing

[87] Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen–progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial.

tiple myeloma. Journal of Clinical Oncology. 2002 Sep 1;**20**(17):3719-3736

[81] Physicians' Desk Reference. 57th ed. Montvale, NJ: Medical Economics; 2003

[84] http://www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095b1.htm

vertebral fractures. The Lancet. 1996;**348**(9041):1535-1541

Annals of Internal Medicine. 1999;**131**(12):935-942

tral prostate in castrated rats. Cancer Research. 2002 Nov 15;**62**(22):6538-6544

and Experimental Therapeutics. 2002 Sep;**302**(3):1055-1061

Cancer Research. 2002 May;**8**(5):1080-1084

Physiological Research. 1998;**47**:237-240

multiple myeloma. Cancer. 2005;**104**(1):118-125

Paris, France. 2008. 1453398

745-751

2000;**49**:S101–S106

82 Osteonecrosis


[116] Geusens P. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clinical Interventions in Aging. 2009;**4**:241-250

[102] Muntoni E, Canaparo R, Della Pepa C, Serpe L, Casale F, Barbera S, et al. Determination of disodium clodronate in human plasma and urine using gas-chromatography–nitrogen-phosphorous detections: Validation and application in pharmacokinetic study.

[103] Han YR, Qin X. Determination of alendronate sodium by ion chromatography with refractive index detection. Journal of Chromatography A. 1996;**719**(2):345-352

[104] Huikko K, Kostiainen R. Analysis of bisphosphonates by capillary electrophoresis–electrospray ionization mass spectrometry. Journal of Chromatography A.

[105] Xie Z, Jiang Y, Zhang D. Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion-pairing agent.

[106] Raccor BS, Sun J, Lawrence RF, Li L, Zhang H, Somerman MJ, et al. Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass

[107] Leo GC, Darrow AL. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magnetic Resonance in Chemistry.

[108] Zhang J, Bowers J, Liu L, Wei S, Gowda GN, Hammoud Z, et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One. 2012;**7**(1):e30181

[109] Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X. Human serum/plasma lipoprotein analysis by NMR: Application to the study of diabetic dyslipidemia. Progress

[110] Kostara CE, Papathanasiou A, Psychogios N, Cung MT, Elisaf MS, Goudevenos J, et al. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of

[111] Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, et al. The human urine

[112] Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine,

[113] Dona AC, Jiménez B, Schäfer H, Humpfer E, Spraul M, Lewis MR, et al. Precision highthroughput proton NMR spectroscopy of human urine, serum, and plasma for large-

[114] Richards SA, & Hollerton JC. Essential Practical NMR for Organic Chemistry. John

[115] Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in

coronary heart disease. Journal of Proteome Research. 2014;**13**(5):2585-2598

plasma, serum and tissue extracts. Nature Protocols. 2007;**2**(11):2692-2703

scale metabolic phenotyping. Analytical Chemistry. 2014;**86**(19):9887-9894

1H NMR metabonomics. Analytical Chemistry. 2006;**78**(13):4281-4290

Journal of Chromatography B. 2004;**799**(1):133-139

Journal of Chromatography A. 2006;**1104**(1):173-178

spectrometry. Journal of Chromatography B. 2013;**935**:54-60

in Nuclear Magnetic Resonance Spectroscopy. 2013;**70**:1-24

metabolome. PLoS One. 2013;**8**(9):e73076

2000;**872**(1):289-298

84 Osteonecrosis

2009;**47**(S1):S20–S25

Wiley & Sons; 2010

